A 2-Part, Open-Label Trial to Evaluate the Pharmacokinetics of MK-3866 Following the Administration of a Single IV Dose to Subjects With Mild, Moderate, and Severe Renal Impairment and End Stage Renal Disease
Phase of Trial: Phase I
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs MK-3866 (Primary)
- Indications Bacterial infections
- Focus Pharmacokinetics
- Sponsors Merck Sharp & Dohme
- 25 Feb 2018 Status changed from active, no longer recruiting to completed.
- 01 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Jan 2018 Planned primary completion date changed from 23 Feb 2018 to 5 Mar 2018.